United States Personalized Medicine Market – Genomic Trends & Forecast 2026–2034

United States Personalized Medicine Market Size and Forecast 2026-2034

United States Personalized Medicine Market is expected to reach US$ 327.97 billion by 2034 from US$ 181.12 billion in 2025, with a CAGR of 6.82% from 2026 to 2034. The United States personalized medicine market is expected to expand significantly during the forecast period, supported by advances in genomics, precision diagnostics, targeted therapies, and increasing emphasis on individualized patient care.

United States Personalized Medicine Industry Overview

The United States personalized medicine market represents one of the most advanced segments of the healthcare industry, driven by rapid progress in genetic science, molecular diagnostics, and precision healthcare technologies. Personalized medicine focuses on tailoring medical treatments, preventive strategies, and healthcare interventions according to an individual's genetic profile, lifestyle factors, and disease characteristics. This approach enables healthcare providers to deliver more targeted therapies, improve treatment outcomes, and minimize adverse drug reactions. Personalized medicine is increasingly being applied across various therapeutic areas, including oncology, cardiovascular diseases, rare genetic disorders, neurology, immunology, and infectious diseases. As healthcare systems continue transitioning toward patient-centered care, the demand for precision-based treatment solutions is growing across the United States.

The United States precision medicine market is primarily driven by the widespread prevalence of chronic diseases, including cancer and cardiovascular conditions. According to the U.S. Food & Drug Administration, seven of the ten leading causes of death in the U.S. are common chronic diseases (CCDs), with diet-related illnesses such as cardiovascular disease, diabetes, obesity, and certain cancers contributing significantly. The U.S. ranks behind 42 countries in diet-related disease rates, while 28 million Americans continue to smoke, increasing the need for targeted therapeutic interventions. Ongoing advancements in genomics and bioinformatics are enhancing personalized therapy development. Additionally, growing pharmaceutical investments in precision medicine research, supportive government initiatives, and the integration of AI and big data analytics are improving patient profiling, treatment customization, and overall market adoption.

The increasing availability of direct-to-consumer genetic testing services is enhancing patient awareness and engagement, acting as a significant growth-inducing factor for the U.S. precision medicine market. Strategic partnerships between research centers and healthcare providers are also accelerating the translation of research into clinical practice. For instance, on August 26, 2024, Care Access announced a multimillion-dollar agreement with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to strengthen pandemic preparedness. The initiative will expand Care Access’s decentralized clinical trial network by adding up to 150 community-based clinicians across 30 regions, underserved community organizations, and nationwide long-term care providers. Growing demand to reduce adverse drug reactions and improve treatment effectiveness is further supporting precision medicine adoption.

Growth Drivers for the United States Personalized Medicine Market

Growing Use of NGS

Next-generation sequencing (NGS), which offers faster and less expensive genetic profiling than conventional technology, is increasing the size of the precision medicine market in the United States. For example, on October 17, 2024, Illumina unveiled the MiSeq i100 Series, their newest benchtop sequencing equipment intended to enhance laboratory next-generation sequencing (NGS) capabilities.  Flexible output capabilities are offered by these systems; the MiSeq i100 Plus, which is expected to be available worldwide in 2025, can generate up to 100 million single end reads each run. Because of this, NGS technology has been quite successful in identifying biomarkers and uncommon mutations, which has greatly accelerated the research process for developing individualized treatment plans. This makes it easier to tailor cancer treatments to each patient's unique genetic profile, especially in oncology. Precision medicine in the US is being greatly advanced by the high market demand for NGS in clinical diagnostics and research, which is expanding market potential and supporting the trends and growth observed across healthcare sectors.

Growing Demand for Targeted and Effective Therapies

Patients and healthcare providers are increasingly seeking treatment approaches that deliver better outcomes while minimizing side effects. Personalized medicine addresses this need by matching therapies to the specific biological characteristics of individual patients. Targeted treatments can improve therapeutic effectiveness by focusing on the underlying mechanisms of disease rather than relying on generalized treatment approaches. This is particularly important in complex conditions such as cancer, where genetic differences can significantly influence treatment response. Pharmaceutical companies are developing precision therapies supported by companion diagnostics to ensure appropriate patient selection. The growing preference for more effective and individualized treatment strategies continues driving demand for personalized medicine solutions throughout the United States.

Increasing Investment in Precision Healthcare Research

Substantial investment in precision healthcare research is contributing significantly to the growth of the personalized medicine market. Government agencies, academic institutions, biotechnology firms, and pharmaceutical companies are actively funding research programs focused on genomics, biomarker discovery, and targeted therapeutics. Collaborative initiatives are accelerating the translation of scientific discoveries into clinical applications. Research efforts aimed at understanding genetic influences on disease susceptibility and treatment response are creating new opportunities for personalized healthcare solutions. The availability of advanced research infrastructure and large-scale patient data resources further supports innovation. These investments continue expanding the scientific foundation of personalized medicine while fostering the development of new diagnostic and therapeutic technologies.

Challenges in the United States Personalized Medicine Market

High Costs of Genetic Testing and Precision Therapies

One of the primary challenges facing the personalized medicine market is the cost associated with advanced diagnostic testing and targeted treatments. Genetic sequencing, molecular profiling, and precision therapies often require sophisticated technologies and specialized expertise, contributing to higher healthcare expenditures. Although technological advancements are improving efficiency, affordability remains a concern for healthcare providers, patients, and payers. Access to personalized medicine services may vary depending on insurance coverage and healthcare resources. Balancing innovation with cost-effectiveness is essential for ensuring broader adoption of personalized healthcare approaches. Addressing economic barriers remains an important priority for industry stakeholders seeking to expand access to precision medicine.

Data Privacy and Ethical Considerations

Personalized medicine relies heavily on the collection, storage, and analysis of genetic and health-related information, creating important privacy and ethical challenges. Protecting sensitive patient data while enabling scientific research and clinical innovation requires robust security measures and regulatory oversight. Concerns regarding data ownership, consent, and potential misuse of genetic information continue to influence public perception and policy discussions. Healthcare organizations and technology providers must ensure compliance with privacy regulations while maintaining patient trust. Ethical considerations surrounding genetic testing, predictive health information, and data sharing require careful management. Successfully addressing these issues is essential for the sustainable growth of the personalized medicine market.

California Personalized Medicine Market

California represents one of the leading personalized medicine markets in the United States due to its concentration of biotechnology companies, research institutions, and advanced healthcare organizations. The state serves as a hub for genomic research, precision diagnostics, and targeted therapeutic development. Healthcare providers increasingly incorporate genetic testing and molecular profiling into clinical practice to improve patient outcomes. Strong collaboration between academic institutions, technology companies, and pharmaceutical organizations accelerates innovation and commercialization of personalized medicine solutions. The state's robust investment environment and highly skilled workforce further support market development. California's leadership in life sciences and healthcare innovation positions it as a major contributor to the growth of personalized medicine nationwide.

The US state of California announced in January 2024 that the city of Bakersfield, the Kern Venture Group, and BIOS Health will work together to construct a precision medicine facility. The facility will undoubtedly serve as a hub for research and development as well as brain clinical trials utilizing BIOS' adaptive dose technology.

Texas Personalized Medicine Market

Texas is emerging as an important market for personalized medicine, supported by its expanding healthcare infrastructure, research capabilities, and growing biotechnology sector. Major medical centers and research institutions are actively involved in genomic medicine, precision oncology, and translational research initiatives. Healthcare providers increasingly utilize personalized treatment approaches to improve disease management and patient care. The state's diverse population also provides valuable opportunities for genetic research and clinical studies. Investments in biotechnology innovation and healthcare modernization continue strengthening the adoption of precision medicine technologies. These factors contribute to Texas's growing significance within the United States personalized medicine market.

New York Personalized Medicine Market

New York plays a prominent role in the personalized medicine market due to its world-class healthcare institutions, research organizations, and pharmaceutical industry presence. The state has become a center for innovation in genomics, molecular diagnostics, and precision therapeutics. Hospitals and healthcare providers increasingly integrate genetic testing and individualized treatment planning into routine clinical care. Research collaborations between academic centers and industry participants support the development of new personalized medicine applications. Growing patient awareness regarding preventive healthcare and targeted therapies further drives market demand. New York continues to contribute significantly to advancements in precision healthcare and personalized treatment strategies.

Florida Personalized Medicine Market

Florida's personalized medicine market is expanding steadily as healthcare providers adopt advanced diagnostic technologies and precision treatment approaches. The state's growing population, strong healthcare sector, and increasing prevalence of chronic diseases support demand for individualized medical care. Research institutions and healthcare organizations are investing in genomic medicine, molecular diagnostics, and patient-centered treatment models. The growing elderly population further increases the need for targeted healthcare solutions that improve treatment effectiveness and quality of life. Advances in healthcare technology and rising awareness of precision medicine benefits continue encouraging adoption throughout the state. These factors position Florida as an increasingly important market within the United States personalized medicine industry.

Recent Developments in United States Personalized Medicine Market

• The IMS Open-Source Consortium was established by Tempus AI, Inc. in June 2026 with the goal of standardizing digital pathology through partnerships with top academic medical institutions, such as YNHH and MSK. Through developments in digital pathology and artificial intelligence, the group hopes to improve clinical procedures.
• At the SelectUSA Investment Summit in Washington, D.C. in May 2026, CTIBIOTECH introduced CTIBIOTECH USA, its North American subsidiary. In order to promote personalized predictive medicine, the subsidiary, which has its headquarters in Philadelphia's Cellicon Valley, will supply the pharmaceutical, biomedical, and dermatocosmetics industries with patented human cell and tissue bioassays and New Approach Methods.

Research Methodology of United States Personalized Medicine Market

The United States Personalized Medicine Market was estimated through a combination of bottom-up and top-down approaches, secondary research, company-level analysis, product-level assessment, and data triangulation. The methodology considered personalized diagnostics, genomic testing, targeted therapeutics, companion diagnostics, pharmacogenomics, personalized cancer treatment, and other precision-medicine applications.

1. Market Definition and Scope

The market was first defined to establish which products, services, and applications were included in the estimation.

The United States Personalized Medicine Market was considered to include revenues generated from healthcare products and services that used an individual's genetic, genomic, molecular, clinical, or other patient-specific information to support disease prevention, diagnosis, treatment selection, treatment monitoring, or therapy optimization.

2. Secondary Research

Extensive secondary research was conducted to establish the underlying market variables.

Information was collected from:

• U.S. government healthcare databases
• Regulatory agencies
• National health organizations
• Medical associations
• Pharmaceutical companies
• Biotechnology companies
• Diagnostic companies
• Genomic testing providers
• Clinical laboratories
• Company annual reports
• Investor presentations
• Product documentation
• Clinical-trial databases
• Scientific publications
• Healthcare industry publications

The research focused on determining the number of relevant tests, therapies, companion diagnostics, sequencing services, patients treated, healthcare facilities using personalized medicine, and revenue generated by major market participants.

3. Bottom-Up Market Estimation

A bottom-up approach was used to calculate the market by individual product, service, application, and company.

The basic calculation was:

Number of Personalized Medicine Tests/Services/Products × Average Revenue per Unit = Market Revenue

For therapeutic applications, the calculation was adjusted to:

Number of Patients Receiving Personalized Therapies × Average Revenue per Treatment = Personalized Medicine Revenue

Separate calculations were performed for diagnostics, testing, therapeutics, and related services.

This prevented high-value targeted therapies from being averaged together with relatively low-priced genetic tests and laboratory services.

4. Company-Level Revenue Analysis

Major personalized medicine companies operating in the United States were identified and analyzed.

Companies were grouped according to their principal activities, such as:

• Genomic testing
• Molecular diagnostics
• Companion diagnostics
• Sequencing
• Targeted therapeutics
• Bioinformatics
• Precision oncology

Publicly reported revenues were reviewed and the proportion attributable to personalized medicine was estimated.

Where companies generated revenue from both personalized and conventional healthcare products, only the relevant personalized-medicine portion was incorporated.

5. Product-Level Validation

Individual products and services were reviewed to validate the company-level estimates.

The assessment considered:

• Product launch
• Regulatory approval
• Indication
• Target patient population
• Testing requirements
• Pricing
• Adoption
• Geographic availability
• Annual revenue

Product-level information was particularly useful when companies did not separately disclose their personalized medicine revenue.

6. Reimbursement-Based Estimation

A reimbursement-based approach was used to validate diagnostic market calculations.

The analysis considered:

• Medicare reimbursement
• Commercial insurance reimbursement
• Medicaid reimbursement
• Laboratory payment levels
• Coverage policies
• Patient out-of-pocket payments

The number of reimbursed tests was multiplied by the estimated reimbursement value.

The calculation was:

Reimbursed Test Volume × Average Reimbursement per Test = Estimated Diagnostic Revenue

Reimbursement rates were adjusted where commercial payer reimbursement differed materially from public-payer reimbursement.

7. Patient-Based Market Estimation

A patient-based methodology was used for personalized treatment applications.

The number of patients eligible for personalized medicine was estimated from disease prevalence and diagnosis data.

The calculation was:

Disease Population × Diagnosed Population × Biomarker Testing Rate × Treatment Adoption Rate × Average Revenue per Patient

This approach was particularly relevant for:

• Oncology
• Rare diseases
• Genetic disorders, etc.

8. Top-Down Market Estimation

A top-down approach was applied to validate the bottom-up estimate.

The broader U.S. healthcare, diagnostics, genomics, biotechnology, and targeted-therapy markets were assessed. The portion associated with personalized medicine was then estimated based on:

• Personalized medicine adoption
• Genetic testing penetration
• Molecular diagnostic utilization
• Targeted therapy adoption
• Companion diagnostic use
• Precision oncology activity

The calculation was structured as:

Relevant U.S. Healthcare/Diagnostics/Therapeutics Market × Personalized Medicine Share = Estimated Personalized Medicine Market

The top-down result was compared with the detailed bottom-up calculation.

9. Supply-Side Validation

The supply side was analyzed by examining the revenues and operations of companies involved in personalized medicine.

Company information was compared across:

• Genomic testing revenues
• Molecular diagnostic revenues
• Sequencing revenues
• Targeted therapy revenues
• Companion diagnostic revenues
• Precision medicine services

The combined company-level assessment was compared with the demand-side market estimate.

This helped identify potential omissions or double counting.

10. Demand-Side Validation

Demand was validated through the number of patients, tests, treatments, healthcare providers, and institutions using personalized medicine.

The demand-side calculation considered:

Patient Population → Eligible Patients → Testing → Treatment Selection → Personalized Treatment → Revenue

This provided a patient-centric perspective and allowed the market estimate to be cross-checked against the supplier-side calculation.

11. Avoiding Double Counting

Particular attention was given to avoiding double counting.

For example, a patient undergoing genomic testing and subsequently receiving a targeted therapy generated revenue in both the diagnostic and therapeutic segments.

These revenues were treated as separate market components only when the market definition included both.

Similarly, revenues reported by pharmaceutical companies and diagnostic companies were reviewed to ensure that the same companion diagnostic revenue was not counted twice through supplier and product-level calculations.

12. Forecast Estimation

The historical market base was subsequently used to forecast future market development.

The forecast model considered:

• Increasing genomic testing
• Expansion of precision oncology
• New targeted therapies
• Growth in companion diagnostics
• Expansion of pharmacogenomics
• Adoption of next-generation sequencing
• Growth in rare-disease diagnosis
• Increasing availability of biomarker-based treatments
• Advances in bioinformatics
• Increasing integration of genomic information into clinical decision-making

Separate growth assumptions were applied to diagnostics, therapeutics, and personalized medicine services.

13. Data Triangulation

The final United States Personalized Medicine Market estimate was established through data triangulation using three major approaches:

Bottom-Up Approach

Test Volume/Patient Volume × Average Revenue

Top-Down Approach

Relevant U.S. Healthcare Market × Personalized Medicine Share

Supply-Side

Company Revenues + Product-Level Assessment

The results were compared and reconciled.

Any significant differences were investigated by reviewing:

• Patient population assumptions
• Testing penetration
• Treatment adoption
• Pricing
• Reimbursement
• Company revenue allocation
• Diagnostic versus therapeutic coverage
• Market definition

14. Final Market Calculation

The final estimate was then cross-checked against the top-down market calculation, company-level revenues, patient-based estimates, reimbursement data and component-level calculations.

Market Segmentations

Product

• Personalized Medicine Therapeutics
• Personalized Medicine Diagnostics
• Personalized Medical Care
• Personalized Nutrition and Wellness

Application

• Oncology
• Infectious disease
• Neurology or Psychiatry
• Cardiovascular
• Others

End User

• Hospitals
• Diagnostic Centers
• Research & Academic Institutes
• Others

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Laboratories
• GE Healthcare, Inc.
• Aadi Bioscience, Inc.
• Illumina, Inc.
• QIAGEN
• Eli Lilly and Company
• Takeda Pharmaceutical Company Ltd
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.

Report Details: